Peptide Half-Life: How Long Do Common Research Compounds Last?
Peptide half-life spans 2 minutes to 3 weeks across 7 research compounds — see which structural modifications extend circulation time, and by how much.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
Peptide half-life varies enormously across research compounds — from a few minutes for unmodified native signaling peptides to several weeks for antibody-conjugated analogues — and that variance is one of the first pharmacokinetic parameters researchers need to understand before designing a dosing or sampling protocol.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
Quick Answer: Peptide half-life in research settings ranges from roughly 2 minutes for native releasing factors like MGF to approximately 3 weeks for antibody-conjugated peptides like maridebart cafraglutide, with the difference almost always driven by a specific structural modification (albumin binding, PEGylation, or antibody fusion) rather than the base peptide sequence itself.
TL;DR:
- Native, unmodified peptides typically clear in minutes because they lack any mechanism to resist rapid enzymatic degradation or renal filtration.
- Structural modifications — fatty-acid albumin binding, DAC conjugation, PEGylation, and antibody fusion — are the primary levers researchers use to extend circulating half-life.
- Half-life directly determines dosing frequency in published protocols: minutes-scale peptides require continuous or frequent dosing, while multi-day or multi-week peptides support once-weekly or once-monthly schedules.
- Published half-life figures are population averages from specific studies and can vary by administration route, species, and assay method.
- The extension from a native peptide's half-life to its modified analogue's half-life can span three or more orders of magnitude within the same peptide family.
How half-life is measured in peptide research
Elimination half-life describes the time required for a compound's plasma concentration to fall by half, typically calculated from serial blood sampling after a single administered dose. For peptides, the two dominant clearance mechanisms are enzymatic degradation — cleavage by peptidases such as dipeptidyl peptidase-4 (DPP-4) or other endopeptidases — and renal filtration, since most therapeutic peptides fall below the roughly 60 kDa glomerular filtration cutoff. Native regulatory peptides are typically cleared within minutes because they evolved for local, transient paracrine signaling rather than sustained systemic exposure. Reported half-life values in the literature are also route-dependent: subcutaneous administration generally produces a longer apparent half-life than intravenous administration because absorption from the injection depot becomes the rate-limiting step, and figures can differ between rodent and human pharmacokinetic studies.
Three structural strategies dominate published half-life-extension approaches: (1) fatty-acid conjugation that promotes reversible serum albumin binding, used in compounds like semaglutide and cagrilintide; (2) Drug Affinity Complex (DAC) or PEGylation chemistry that achieves a similar albumin-binding or steric-shielding effect, as in CJC-1295 with DAC; and (3) antibody-fragment fusion, which leverages the neonatal Fc receptor (FcRn) recycling pathway that normally extends antibody half-life to weeks, as seen in maridebart cafraglutide. Each strategy targets a different clearance bottleneck, and researchers select among them based on how long sustained target engagement needs to last in a given experimental design.
Ranked from shortest to longest: 7 compounds compared
1. MGF (Mechano Growth Factor)
Native MGF, the IGF-1 splice variant produced locally in skeletal muscle following mechanical loading, has a reported half-life of only minutes in circulation. This is consistent with its proposed biological role as a local autocrine/paracrine signal rather than a systemic hormone — the mechanically stretched muscle fiber's own environment, not distal tissue, is the intended target. Because native MGF clears so quickly, most research groups studying its downstream effects use PEGylated analogues specifically to extend the observation window (PMID 12055211 — "Mechano-growth factor: a splice variant of IGF-1 induced by mechanical loading" (Journal of Physiology, 2002)).
2. CJC-1295 without DAC
CJC-1295 in its non-DAC form (also called Modified GRF 1-29) is engineered with amino acid substitutions that confer partial resistance to DPP-4 degradation relative to native GHRH, but it still clears in approximately 30 minutes — a modest improvement over native growth hormone-releasing hormone's few-minute half-life, not a dramatic one. This preserves a pulsatile pattern of growth hormone release in preclinical models, which is the specific research use case that distinguishes it from its DAC-conjugated counterpart (PMID 16352683 — "Sustained release of growth hormone-releasing hormone analogue (CJC-1295) in healthy adults" (Journal of Clinical Endocrinology & Metabolism, 2006)).
3. IGF-1 LR3
IGF-1 LR3 extends native IGF-1's roughly 12–15 minute half-life to approximately 20–30 hours through an N-terminal 13-amino-acid extension combined with an Arg3 substitution that reduces binding-protein sequestration. This places it in an intermediate tier — far longer than unmodified signaling peptides, but still substantially shorter than the multi-day compounds further down this list — making it a common choice in research designs that require sustained but not week-long receptor engagement (PMID 41418663 — "Provisional Treatment of Volumetric Muscle Loss With Insulin-like Growth Factor 1 Releasing Muscle Void Fillers." (2026)). Half-life data here is further corroborated in preclinical binding-protein studies referenced within the compound's full research profile.
4. Cagrilintide
An amylin-receptor agonist, cagrilintide reaches a half-life of approximately 159–195 hours (roughly 6.5–8 days) through an N-terminally linked C20 fatty acid that promotes reversible albumin binding. This extension supports the once-weekly subcutaneous dosing schedule used in its published Phase 3 co-administration trial with semaglutide (PMID 40544432 — "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1)." (New England Journal of Medicine, 2026)).
5. Semaglutide
Semaglutide achieves an approximately 168-hour half-life via a C18 fatty diacid modification that enables reversible albumin binding, alongside an Aib-8 substitution that independently blocks DPP-4 cleavage at the peptide's N-terminus. The combination of both mechanisms — protease resistance and albumin binding — is why semaglutide's half-life is roughly twelve times longer than liraglutide's C16-modified, single-mechanism design, and it is the pharmacokinetic basis for once-weekly dosing across its published trial programs (PMID 42027588 — reference case study discussing semaglutide pharmacology (2026)).
6. CJC-1295 with DAC
The DAC-conjugated form of CJC-1295 covalently links to circulating serum albumin via a maleimidopropionic acid linker, extending half-life to approximately 6–8 days — around 300 times longer than its non-DAC counterpart. Single-dose studies in healthy adults documented sustained growth hormone and IGF-1 elevation across this entire window, supporting research protocols that require continuous rather than pulsatile GHRH receptor stimulation (PMID 16352683 — "Sustained release of growth hormone-releasing hormone analogue (CJC-1295) in healthy adults" (Journal of Clinical Endocrinology & Metabolism, 2006)).
7. Maridebart cafraglutide
The longest half-life in this comparison belongs to maridebart cafraglutide (AMG 133), which fuses GLP-1 receptor-agonist peptide sequences to an antibody fragment, extending circulating half-life to roughly three weeks. This antibody-conjugate architecture is mechanistically distinct from the fatty-acid albumin-binding approach used by semaglutide and cagrilintide — it instead leverages the FcRn recycling pathway that normally protects circulating antibodies from lysosomal degradation — and is the basis for the monthly-or-less-frequent dosing interval studied in its Phase 2 trial (PMID 40549887 — "Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial." (2025)).
Comparison table
| Compound | Approx. half-life | Extension mechanism | Typical research dosing interval |
|---|---|---|---|
| MGF (native) | Minutes | None (native peptide) | Continuous/local signaling models |
| CJC-1295 (no DAC) | ~30 minutes | DPP-4-resistant substitutions | Pulsatile, frequent dosing |
| IGF-1 LR3 | ~20–30 hours | N-terminal extension + Arg3 substitution | Daily or near-daily |
| Cagrilintide | ~159–195 hours | C20 fatty acid, albumin binding | Once weekly |
| Semaglutide | ~168 hours | C18 fatty diacid + Aib-8 substitution | Once weekly |
| CJC-1295 with DAC | ~6–8 days | DAC albumin conjugation | Once weekly |
| Maridebart cafraglutide | ~3 weeks | Antibody-fragment fusion (FcRn recycling) | Monthly or less frequent |
Researchers cross-referencing these figures against additional compounds can use the site's half-life comparison tool to visualize the full research library's pharmacokinetic range in one view.
Why this matters for research design
Half-life determines the practical dosing interval used across nearly every published research protocol in this comparison — compounds with minute-scale clearance are studied under continuous-infusion or frequent-bolus designs, while multi-day and multi-week compounds are studied under once-weekly or once-monthly schedules. Half-life also affects experimental sampling design: a study measuring pharmacodynamic response to a 30-minute-half-life compound needs sampling timepoints on a minutes-to-hours scale, while a study of a three-week-half-life compound requires a sampling window spanning weeks to capture the full elimination curve. Researchers should also note that published half-life figures are typically derived from a specific administration route and population — subcutaneous dosing in healthy adults, for example — and may not transfer directly to other routes or preclinical species without route- and species-specific validation.
Cited studies
- PMID 12055211 — "Mechano-growth factor: a splice variant of IGF-1 induced by mechanical loading" (Journal of Physiology, 2002). https://doi.org/10.1113/jphysiol.2002.018424
- PMID 16352683 — "Sustained release of growth hormone-releasing hormone analogue (CJC-1295) in healthy adults" (Journal of Clinical Endocrinology & Metabolism, 2006). https://doi.org/10.1210/jc.2005-1536
- PMID 41418663 — "Provisional Treatment of Volumetric Muscle Loss With Insulin-like Growth Factor 1 Releasing Muscle Void Fillers." (2026). https://doi.org/10.1016/0303-7207(92)90159-4
- PMID 40544432 — "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1)." (New England Journal of Medicine, 2026). https://doi.org/10.1056/NEJMoa2502081
- PMID 42027588 — reference case study discussing semaglutide pharmacology (2026). https://doi.org/10.1056/NEJMoa1607141
- PMID 40549887 — "Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial." (2025). https://doi.org/10.1056/NEJMoa2504214
Frequently asked questions
Q: What is the shortest peptide half-life among common research compounds?
A: Among the compounds compared here, native MGF has the shortest reported half-life at only a few minutes in circulation, consistent with its role as a locally acting autocrine signal rather than a systemically circulating hormone. Most unmodified regulatory peptides fall into this minutes-scale category before any half-life-extending modification is applied.
Q: Why do some peptides have a half-life of minutes while others last weeks?
A: The difference comes almost entirely from structural modifications rather than the base peptide sequence. Fatty-acid conjugation, DAC or PEGylation chemistry, and antibody-fragment fusion each interfere with a specific clearance mechanism — enzymatic degradation or renal filtration — and can extend half-life from minutes to multiple weeks depending on which mechanism and how many are combined.
Q: How is peptide half-life determined in a research study?
A: Half-life is typically calculated from serial plasma concentration measurements following a single administered dose, identifying the time required for concentration to fall by 50%. Values can differ by administration route (subcutaneous versus intravenous), species (rodent versus human), and the specific pharmacokinetic assay used, so published figures should always be checked against the study's exact methodology.
Q: Does a longer half-life mean a more potent peptide?
A: No. Half-life describes how long a compound remains in circulation, not its receptor binding affinity or downstream signaling potency. A short-half-life peptide can be highly potent at the receptor level while clearing quickly, and a long-half-life compound is not automatically more effective — the two properties are pharmacologically independent.
Q: Which peptides in this comparison support once-weekly research dosing?
A: Cagrilintide, semaglutide, and CJC-1295 with DAC all fall in the roughly 150-hour-to-8-day range that has supported once-weekly dosing schedules in their respective published trials, driven by albumin-binding fatty-acid or DAC-conjugation chemistry that slows systemic clearance to that timescale.
See also:
- CJC-1295 vs CJC-1295 with DAC: Pulsatile vs Sustained GH Release — a deeper head-to-head on how DAC conjugation changes half-life and dosing pattern within a single peptide family.
- Semaglutide Mechanism of Action: GLP-1 Receptor Agonism in Preclinical Research — covers the receptor pharmacology behind semaglutide's albumin-binding half-life extension in more detail.
- IGF-1 LR3, DES(1-3) IGF-1, and PEG-MGF: IGF-1 Analogue Cluster — compares half-life-extension strategies across the broader IGF-1 analogue family.
For laboratory research purposes only. Not for human or animal consumption. Compounds described are not approved by the FDA for human or veterinary use unless explicitly stated.